[go: up one dir, main page]

HUP0400698A3 - Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity - Google Patents

Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity

Info

Publication number
HUP0400698A3
HUP0400698A3 HU0400698A HUP0400698A HUP0400698A3 HU P0400698 A3 HUP0400698 A3 HU P0400698A3 HU 0400698 A HU0400698 A HU 0400698A HU P0400698 A HUP0400698 A HU P0400698A HU P0400698 A3 HUP0400698 A3 HU P0400698A3
Authority
HU
Hungary
Prior art keywords
receptor antagonist
reduced immunogenicity
modified interleukin
interleukin
modified
Prior art date
Application number
HU0400698A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0400698A2 publication Critical patent/HUP0400698A2/hu
Publication of HUP0400698A3 publication Critical patent/HUP0400698A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/545IL-1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015Drug-containing film-forming compositions, e.g. spray-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20Protein or domain folding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU0400698A 2001-02-06 2002-02-05 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity HUP0400698A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01102573 2001-02-06
EP01103954 2001-02-19
PCT/EP2002/001170 WO2002062375A1 (en) 2001-02-06 2002-02-05 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity

Publications (2)

Publication Number Publication Date
HUP0400698A2 HUP0400698A2 (hu) 2004-06-28
HUP0400698A3 true HUP0400698A3 (en) 2006-01-30

Family

ID=26076457

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400698A HUP0400698A3 (en) 2001-02-06 2002-02-05 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity

Country Status (12)

Country Link
US (1) US20040076991A1 (hu)
EP (1) EP1357934A1 (hu)
JP (1) JP2004519230A (hu)
KR (1) KR20030074790A (hu)
CN (1) CN1549723A (hu)
BR (1) BR0207014A (hu)
CA (1) CA2437214A1 (hu)
HU (1) HUP0400698A3 (hu)
MX (1) MXPA03007004A (hu)
PL (1) PL362412A1 (hu)
RU (1) RU2003125640A (hu)
WO (1) WO2002062375A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544011A (en) * 2003-06-10 2009-02-28 Univ Melbourne Immunomodulating compositions uses therefor and processes for their production
RS57852B1 (sr) * 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
GB0708376D0 (en) * 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
EP2598526B1 (en) 2010-07-29 2018-09-05 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
ES2600616T3 (es) * 2011-03-14 2017-02-10 Phlogo Aps Antagonistas del receptor de la interleucina-1
CA2869786A1 (en) 2012-06-08 2013-12-12 Alkermes, Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ, インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス,インク. 改質された毒素
KR20230130155A (ko) * 2016-08-19 2023-09-11 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
JP7282378B2 (ja) 2016-12-07 2023-05-29 ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド IL-1Ra cDNA
CN114761412B (zh) 2019-11-25 2024-10-11 阿尔克姆斯有限公司 取代的大环化合物和相关治疗方法
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
EP4314073A4 (en) 2021-03-24 2025-02-19 Alkermes, Inc. Upar antibodies and fusion proteins with the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
AU8016094A (en) * 1993-10-12 1995-05-04 Mary Lake Polan Method of contraception
IT1269989B (it) * 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
ATE319745T1 (de) * 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
CA2342967A1 (en) * 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
WO2001042304A1 (en) * 1999-12-10 2001-06-14 Amgen, Inc. Interleukin-1 receptor antagonist-related molecules and uses thereof

Also Published As

Publication number Publication date
WO2002062375A1 (en) 2002-08-15
CN1549723A (zh) 2004-11-24
CA2437214A1 (en) 2002-08-15
MXPA03007004A (es) 2003-11-18
PL362412A1 (en) 2004-11-02
BR0207014A (pt) 2004-02-25
RU2003125640A (ru) 2005-03-10
EP1357934A1 (en) 2003-11-05
KR20030074790A (ko) 2003-09-19
HUP0400698A2 (hu) 2004-06-28
JP2004519230A (ja) 2004-07-02
US20040076991A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2002324624A1 (en) Sequestered antagonist formulations
AU2002347022A1 (en) Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AUPR769501A0 (en) Cytokine receptor 1
EP1388310A4 (en) CUSHION STRUCTURE
IL158354A0 (en) Adjustable seats
GB2387913B (en) Interface detector
AU2001273032A1 (en) Cytokine receptor zcytor17
HUP0400698A3 (en) Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
AU2003285042A1 (en) Nuclear hormone receptor compounds, products and methods employing same
AU2002252460A1 (en) Human cytokine receptor
AU2003255501A1 (en) Cxcr4 receptor antagonists
AU2002305944A1 (en) Mouse cytokine receptor
EP1423432A4 (en) ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2002254076A1 (en) Chemokine receptors and disease
AU2001277980A1 (en) Human cytokine receptor
AU2002325164A1 (en) Receptor, the use thereof, and mouse antibodies
AU2001249573A1 (en) Chemokine receptor antagonists
AU2001223882A1 (en) Receptor
GB0201471D0 (en) Device for document preparation
AU2002367281A8 (en) Isolated cytokine receptor licr-2
WO2003006609A9 (en) Human cytokine receptor
AU2003242244A1 (en) Chemokine receptor antagonist
AU2003242852A1 (en) Nuclear hormone receptor
AU2002338040A1 (en) Receptor antagonist

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees